The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
An essential receptor for adeno-associated virus infection
Open accessAbstract
Adeno-associated virus (AAV) vectors are currently the leading candidates for virus-based gene therapies because of their broad tissue tropism, non-pathogenic nature and low immunogenicity. They have been successfully used in clinical trials to treat hereditary diseases such as haemophilia B (ref. 2), and have been approved for treatment of lipoprotein lipase deficiency in Europe. Considerable efforts have been made to engineer AAV variants with novel and biomedically valuable cell tropisms to allow efficacious systemic administration, yet basic aspects of AAV cellular entry are still poorly understood. In particular, the protein receptor(s) required for AAV entry after cell attachment remains unknown. Here we use an unbiased genetic screen to identify proteins essential for AAV serotype 2 (AAV2) infection in a haploid human cell line. The most significantly enriched gene of the screen encodes a previously uncharacterized type I transmembrane protein, KIAA0319L (denoted hereafter as AAV receptor (AAVR)). We characterize AAVR as a protein capable of rapid endocytosis from the plasma membrane and trafficking to the trans-Golgi network. We show that AAVR directly binds to AAV2 particles, and that anti-AAVR antibodies efficiently block AAV2 infection. Moreover, genetic ablation of AAVR renders a wide range of mammalian cell types highly resistant to AAV2 infection. Notably, AAVR serves as a critical host factor for all tested AAV serotypes. The importance of AAVR for in vivo gene delivery is further highlighted by the robust resistance of Aavr(-/-) (also known as Au040320(-/-) and Kiaa0319l(-/-)) mice to AAV infection. Collectively, our data indicate that AAVR is a universal receptor involved in AAV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The peptide insertion at position R588 in R100 sterically prohibits the close proximity between R585 and R588 required for heparan sulfate binding ( Fig. 5 B), suggesting a plausible mechanism for enhanced transit through the heparan sulfate-rich ILM barrier.”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Maxfield, F. R., & McGraw, T. E. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1315 · Cited by 1,729
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Ebola virus entry requires the cholesterol transporter Niemann–Pick C1
Carette, J. E., Raaben, M., Wong, A. C., Herbert, A. S., Obernosterer, G., Mulherkar, N., Kuehne, A. I., Kranzusch, P. J., Griffin, A. M., Ruthel, G., et al. (2011) · Nature · doi:10.1038/nature10348 · Cited by 1,303
Self-citationMannose 6-phosphate receptors: new twists in the tale
Ghosh, P., Dahms, N. M., & Kornfeld, S. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1050 · Cited by 1,086
A Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells
Campeau, E., Ruhl, V. E., Rodier, F., Smith, C. L., Rahmberg, B. L., Fuss, J. O., Campisi, J., Yaswen, P., Cooper, P. K., & Kaufman, P. D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006529 · Cited by 964
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
“Recently, an uncharacterized type I membrane protein, AAVR (KIAA0319L), was identified as a critical receptor for AAV cell binding and internalization [37].”
BackgroundA Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons
Tervo, D. G. R., Hwang, B.-Y., Viswanathan, S., Gaj, T., Lavzin, M., Ritola, K. D., Lindo, S., Michael, S., Kuleshova, E., Ojala, D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.09.021 · Cited by 1,179
“…insertion might support enhanced binding to an existing cellular co-factor in the AAV pathway (e.g., the recently identified common AAV receptor; Pillay et al., 2016), or it might create a novel interaction with the cellular machinery, such as a cell-surface receptor and/or a component of the…”
BackgroundAdeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
“43 Another universal host protein, G protein-coupled receptor 108 (GPR108), plays a role in the transduction of several rAAV serotypes.”
BackgroundEmerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
“Recently, a universal multiserotype AAV receptor (AAVR) has been identified.(14) Because AAVR seems to be essential to AAV infection, serotype-specific co-receptors and additional factors should account for the diverse tropism of AAV capsid variants.”
BackgroundZingg, B., Chou, X.-L., Zhang, Z.-G., Mesik, L., Liang, F., Tao, H. W., & Zhang, L. I. (2017) · Neuron · doi:10.1016/j.neuron.2016.11.045 · Cited by 752
Tabebordbar, M., Lagerborg, K. A., Stanton, A., King, E. M., Ye, S., Tellez, L., Krunnfusz, A., Tavakoli, S., Widrick, J. J., Messemer, K. A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.028 · Cited by 506
AAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
“42 Different non-exclusive functions have been proposed for AAVR in AAV infection: AAVR interacts with AAV either at the surface and aids in AAV cellular uptake into an endosomal pathway, the interaction occurs in the early endosomal system and facilitates traf fi cking to the trans -Golgi, AAVR…”
BackgroundGene Therapy Leaves a Vicious Cycle
Goswami, R., Subramanian, G., Silayeva, L., Newkirk, I., Doctor, D., Chawla, K., Chattopadhyay, S., Chandra, D., Chilukuri, N., & Betapudi, V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00297 · Cited by 347
“Recently, AAVR has been identified as a universal host cell receptor for AAV infections (144).”
BackgroundIn vivo tissue-tropism of adeno-associated viral vectors
Srivastava, A. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.08.003 · Cited by 347
Körbelin, J., Dogbevia, G., Michelfelder, S., Ridder, D. A., Hunger, A., Wenzel, J., Seismann, H., Lampe, M., Bannach, J., Pasparakis, M., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506078 · Cited by 252
“EMBO Molecular Medicine Vol 8 | No 6 | 2016 ª 2016 The Authors be essential for cellular uptake of a variety of AAV serotypes (Pillay et al, 2016).”
BackgroundBucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Huang, Q., Chan, K. Y., Tobey, I. G., Chan, Y. A., Poterba, T., Boutros, C. L., Balazs, A. B., Daneman, R., Bloom, J. M., Seed, C., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0225206 · Cited by 234
Mingozzi, F., & High, K. A. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041936 · Cited by 206
PLA2G16 represents a switch between entry and clearance of Picornaviridae
Staring, J., von Castelmur, E., Blomen, V. A., van den Hengel, L. G., Brockmann, M., Baggen, J., Thibaut, H. J., Nieuwenhuis, J., Janssen, H., van Kuppeveld, F. J. M., et al. (2017) · Nature · doi:10.1038/nature21032 · Cited by 201
Self-citationTwenty-Five Years of Structural Parvovirology
Mietzsch, M., Pénzes, J. J., & Agbandje-McKenna, M. (2019) · Viruses · doi:10.3390/v11040362 · Cited by 197
Pillay, S., Zou, W., Cheng, F., Puschnik, A. S., Meyer, N. L., Ganaie, S. S., Deng, X., Wosen, J. E., Davulcu, O., Yan, Z., et al. (2017) · Journal of Virology · doi:10.1128/jvi.00391-17 · Cited by 187
“However, clustered regularly interspaced short palindromic repeat (CRISPR)-mediated knockout of FGFR-1 and c-Met in several cell lines did not substantially affect AAV2 transduction (21), suggesting that these coreceptors have accessory rather than essential roles in AAV2 transduction.”
BackgroundInfluentialSelf-citationVascular Endothelial Cells: Heterogeneity and Targeting Approaches
Hennigs, J. K., Matuszcak, C., Trepel, M., & Körbelin, J. (2021) · Cells · doi:10.3390/cells10102712 · Cited by 178
“The cellular uptake of most AAV serotypes by receptor-mediated endocytosis further requires the presence of the transmembrane dyslexia-associated protein KIAA0319, also termed AAVR (for AAV receptor) [323].”
BackgroundA CRISPR toolbox to study virus–host interactions
Puschnik, A. S., Majzoub, K., Ooi, Y. S., & Carette, J. E. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.29 · Cited by 191
Self-citationWassmer, S. J., Carvalho, L. S., György, B., Vandenberghe, L. H., & Maguire, C. A. (2017) · Scientific Reports · doi:10.1038/srep45329 · Cited by 164
“In this study, we found that exo-AAV particles are however, dependent on the universal AAV receptor (AAVR), which is located on the cell surface but highly involved in intracellular trafficking 20 .”
InfluentialHammond, S. L., Leek, A. N., Richman, E. H., & Tjalkens, R. B. (2017) · PLOS ONE · doi:10.1371/journal.pone.0188830 · Cited by 160
The Interplay between Adeno-Associated Virus and Its Helper Viruses
Meier, A. F., Fraefel, C., & Seyffert, M. (2020) · Viruses · doi:10.3390/v12060662 · Cited by 162
“An unbiased genetic screen identified a transmembrane protein, termed AAV receptor (AAVR), as an essential factor for AAV transduction for multiple serotypes [44].”
BackgroundLiguore, W. A., Domire, J. S., Button, D. A., Wang, Y., Dufour, B. D., Srinivasan, S., & McBride, J. L. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.07.017 · Cited by 163
“B is then able to transduce neurons and glia via binding to cell surface receptors already identified for AAV9, including N-linked galactose(73) and the universal AAV receptor, AAVR.(73,74)”
BackgroundViral Vectors for Gene Transfer
Chen, Y. H., Keiser, M. S., & Davidson, B. L. (2018) · Current Protocols in Mouse Biology · doi:10.1002/cpmo.58 · Cited by 146
“AAV enters cells by binding to cell surface sugars (such as sialic acid, galactose, or heparin sulfate) and protein receptors (AAV receptor, AAVR; Pillay et al., 2016), and then internal-izes via clatherin-dependent or -independent cytosis.”
Targeting microglia with lentivirus and AAV: Recent advances and remaining challenges
Maes, M. E., Colombo, G., Schulz, R., & Siegert, S. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134310 · Cited by 145
“Co-receptors such as the integrins Itgav and Itgb5 [66,67], hepatocyte growth factor receptor (c-MET) [68], and fibroblast growth factor receptor 1 (FGFR1) [69,70] have been implicated in AAV attachment and internalization, from which the integrins are expressed in microglia.”
Genome Editing Abrogates Angiogenesis in Vivo
Huang, X., Zhou, G., Wu, W., Duan, Y., Ma, G., Song, J., Xiao, R., Vandenberghe, L., Zhang, F., D’Amore, P. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00140-3 · Cited by 142
Adeno-associated virus (AAV) cell entry: structural insights
Meyer, N., & Chapman, M. S. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.09.005 · Cited by 147
Self-citationNonintegrating Gene Therapy Vectors
Athanasopoulos, T., Munye, M. M., & Yáñez‐Muñoz, R. J. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.007 · Cited by 136
GPR108 Is a Highly Conserved AAV Entry Factor
Dudek, A. M., Zabaleta, N., Zinn, E. M., Pillay, S., Zengel, J. R., Porter, C. L., Franceschini, J. S., Estelien, R., Carette, J. E., Zhou, G. L., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.005 · Cited by 144
“Only recently, a haploid genetic screen identified a highly conserved AAV entry receptor, AAVR.20 In this study, in order to better understand the cellular entry determinants of a wide range of AAV variants, we undertook a genomewide CRISPR screen using a divergent AAV serotype, rh32.”
BackgroundInfluentialSelf-citationAdeno-associated Virus Vectors in Gene Therapy
Mary, B., Khan, N., Arumugam, S., Saxena, H., Kumar, M., Manimaran, P., Chattopadhyay, S., & Jayandharan, G. R. (2018) · Springer eBooks · doi:10.1007/978-981-13-0481-1_2 · Cited by 127
Journey to the Center of the Cell: Tracing the Path of AAV Transduction
Dhungel, B. P., Bailey, C. G., & Rasko, J. E. J. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.09.010 · Cited by 122
Viral Vectors for Neural Circuit Mapping and Recent Advances in Trans-synaptic Anterograde Tracers
Xu, X., Holmes, T. C., Luo, M., Beier, K. T., Horwitz, G. D., Zhao, F., Zeng, W., Hui, M., Semler, B. L., & Sandri-Goldin, R. M. (2020) · Neuron · doi:10.1016/j.neuron.2020.07.010 · Cited by 133
An Alternate Route for Adeno-associated Virus (AAV) Entry Independent of AAV Receptor
Dudek, A. M., Pillay, S., Puschnik, A. S., Nagamine, C. M., Cheng, F., Qiu, J., Carette, J. E., & Vandenberghe, L. H. (2018) · Journal of Virology · doi:10.1128/jvi.02213-17 · Cited by 128
“Aavr KO mice carrying a 1-bp deletion (CCCGCTTCC—GGGTTTTGCCAGGA, where — marks the deletion) resulting in a frameshift mutation in Aavr (33) or WT cage mates were intravenously injected with 1 1011 VG/mouse via the retro-orbital route.”
BackgroundMethodResultInfluentialSelf-citationIntracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions
Riyad, J. M., & Weber, T. (2021) · Gene Therapy · doi:10.1038/s41434-021-00243-z · Cited by 146
In Vivo Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene Therapy
Choudhury, S., Fitzpatrick, Z., Harris, A. F., Maitland, S. A., Ferreira, J. S., Zhang, Y., Ma, S., Sharma, R. B., Gray‐Edwards, H. L., Johnson, J. A., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.84 · Cited by 125
Small But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution
Grimm, D., & Büning, H. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.172 · Cited by 120
“16 Evidence for the seminal role of this receptor included findings that AAVR knockout cells and mice were largely refractory to AAV infection, and that this effect could be rescued in cultured cells through AAVR over-expression.”
CRISPR/Cas9‑mediated cervical cancer treatment targeting human papillomavirus E6
Yoshiba, T., Saga, Y., Urabe, M., Uchibor, R., Matsubara, S., Fujiwara, H., & Mizukami, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.9815 · Cited by 128
“A recent study revealed the presence of KIAA0319L, a receptor essential for AAV transduction of human cells (26).”
BackgroundA systems approach to infectious disease
Eckhardt, M., Hultquist, J. F., Kaake, R. M., Hüttenhain, R., & Krogan, N. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0212-5 · Cited by 125
An evolved AAV variant enables efficient genetic engineering of murine T cells
Nyberg, W. A., Ark, J., To, A., Clouden, S., Reeder, G. C., Muldoon, J. J., Chung, J.-Y., Xie, W. H., Allain, V., Steinhart, Z., et al. (2023) · Cell · doi:10.1016/j.cell.2022.12.022 · Cited by 118
“Encouragingly, we also identified Gpr108 (Figures 2C and 2D), which has been reported together with AAVR as an important regulator of AAV processing.(28,30) Both hits provided confidence in the sensitivity of the screen.”
Baruteau, J., Waddington, S. N., Alexander, I. E., & Gissen, P. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0053-3 · Cited by 114
Adeno-associated virus 2 bound to its cellular receptor AAVR
Zhang, R., Cao, L., Cui, M., Sun, Z., Hu, M., Zhang, R., Stuart, W. S., Zhao, X., Yang, Z., Li, X., et al. (2019) · Nature Microbiology · doi:10.1038/s41564-018-0356-7 · Cited by 111
Completion of the AAV Structural Atlas: Serotype Capsid Structures Reveals Clade-Specific Features
Mietzsch, M., Jose, A., Chipman, P. R., Bhattacharya, N., Daneshparvar, N., McKENNA, R. V., & Agbandje‐McKenna, M. (2021) · Viruses · doi:10.3390/v13010101 · Cited by 117
“Among the cellular receptors are sialic acids [22–24], heparan sulfate proteoglycans (HSPG) [25–29], terminal galactose [30,31], sulfated N-acetyl-lactosamine [32], AAVR [33], laminin [34], αvβ1 integrin [35], αvβ5 integrin [36], the hepatocyte growth factor receptor [37], the fibroblast growth factor receptor [38], a…”
BackgroundSystemic delivery of adeno-associated viral vectors
Duan, D. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.07.006 · Cited by 109
Westhaus, A., Cabanes-Creus, M., Rybicki, A., Baltazar, G., Navarro, R. G., Zhu, E., Drouyer, M., Knight, M., Albu, R. F., Ng, B. H., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.264 · Cited by 102
“To this end, AAV4 is the only AAV variant included in our screen that is known to enter cells independently of the recently described AAV receptor (AAVR).(55,56) Studies show that AAVR is only weakly expressed on airway epithelial cells, and the expression is limited to the basolateral side of the epithelium.”
BackgroundStrategy to detect pre-existing immunity to AAV gene therapy
Falese, L., Sandza, K., Yates, B., Triffault, S., Gangar, S., Long, B., Tsuruda, L., Carter, B., Vettermann, C., Zoog, S. J., et al. (2017) · Gene Therapy · doi:10.1038/gt.2017.95 · Cited by 101
KREMEN1 Is a Host Entry Receptor for a Major Group of Enteroviruses
Staring, J., van den Hengel, L. G., Raaben, M., Blomen, V. A., Carette, J. E., & Brummelkamp, T. R. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.03.019 · Cited by 106
Self-citationPriming Human Repopulating Hematopoietic Stem and Progenitor Cells for Cas9/sgRNA Gene Targeting
Charlesworth, C. T., Camarena, J., Cromer, M. K., Vaidyanathan, S., Bak, R. O., Carte, J. M., Potter, J., Dever, D. P., & Porteus, M. H. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.04.017 · Cited by 109
“We found that K562 AAVR KO cells could not be transduced well by scAAV6 under non-electroporated conditions or when scAAV6 was added immediately after electroporation, demonstrating that the EAT effect occurs through an AAVR-dependent pathway.(33)”
BackgroundOjala, D. S., Sun, S., Santiago-Ortiz, J. L., Shapiro, M. G., Romero, P. A., & Schaffer, D. V. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.006 · Cited by 97
“After characterizing the different glycan-binding properties of SCH2 and SCH9, we examined whether both variants retained utilization of AAVR, a newly described protein receptor that is critical for AAV infection in natural AAV serotypes.(62) SCH2, SCH9, and the AAV2 control were all clearly dependent on AAVR (Figure…”
BackgroundEfficient whole brain transduction by systemic infusion of minimally purified AAV-PHP.eB
Konno, A., & Hirai, H. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2020.108914 · Cited by 104
Host determinants of adeno-associated viral vector entry
Pillay, S., & Carette, J. E. (2017) · Current Opinion in Virology · doi:10.1016/j.coviro.2017.06.003 · Cited by 105
Self-citationCFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes
Steines, B. R., Dickey, D. D., Bergen, J., Excoffon, K. J. D. A., Weinstein, J. R., Li, X., Yan, Z., Alaiwa, M. H. A., Shah, V. S., Bouzek, D. C., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88728 · Cited by 100
“AAVR was shown to be sufficient and required for different AAV serotypes.”
BackgroundInfluentialLi, X., Salvia, S. L., Liang, Y., Adamiak, M., Kohlbrenner, E., Jeong, D., Chepurko, E., Ceholski, D. K., López-Gordo, E., Yoon, S., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.063759 · Cited by 96
Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing
Maule, G., Casini, A., Montagna, C., Ramalho, A. S., De Boeck, K., Debyser, Z., Carlon, M. S., Petris, G., & Cereseto, A. (2019) · Nature Communications · doi:10.1038/s41467-019-11454-9 · Cited by 86
A lung tropic AAV vector improves survival in a mouse model of surfactant B deficiency
Kang, M. H., van Lieshout, L. P., Xu, L., Domm, J. M., Vadivel, A., Renesme, L., Mühlfeld, C., Hurskainen, M., Mižíková, I., Pei, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17577-8 · Cited by 91
Structure of the gene therapy vector, adeno-associated virus with its cell receptor, AAVR
Meyer, N. L., Hu, G., Davulcu, O., Xie, Q., Noble, A. J., Yoshioka, C., Gingerich, D. S., Trzynka, A., David, L., Stagg, S. M., et al. (2019) · eLife · doi:10.7554/elife.44707 · Cited by 83
Self-citationAdeno-associated virus (AAV) vectors: Rational design strategies for capsid engineering
Lee, E. J., Guenther, C. M., & Suh, J. (2018) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2018.09.004 · Cited by 83
“A novel receptor AAVR recently identified appears to be required for infection for some variants [20].”
BackgroundDivergent engagements between adeno-associated viruses with their cellular receptor AAVR
Zhang, R., Xu, G., Cao, L., Sun, Z., He, Y., Cui, M., Sun, Y., Li, S.-T., Li, H., Qin, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11668-x · Cited by 82
AAV-Mediated Gene Delivery to 3D Retinal Organoids Derived from Human Induced Pluripotent Stem Cells
Garita-Hernandez, M., Routet, F., Guibbal, L., Khabou, H., Toualbi, L., Riancho, L., Reichman, S., Duebel, J., Sahel, J.-A., Goureau, O., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030994 · Cited by 82
“The recently discovered AAVR (KIAA0319L), recognized as a universal AAV receptor, was also included in the present study [22].”
BackgroundMapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier
Albright, B. H., Storey, C. M., Murlidharan, G., Castellanos Rivera, R. M., Berry, G. E., Madigan, V. J., & Asokan, A. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.017 · Cited by 82
“Recently, a transmembrane protein, KIAA0319L (AAVR), has been identified as a universal receptor for multiple AAV serotypes.(11) These factors, along with tissue glycosylation patterns, contribute to the varying tissue tropisms of different AAV serotypes.”
BackgroundMechanisms of receptor-mediated transcytosis at the blood-brain barrier
Baghirov, H. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113595 · Cited by 86
Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus
Miles, L. A., Burga, L. N., Gardner, E. E., Bostina, M., Poirier, J. T., & Rudin, C. M. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93472 · Cited by 83
Cellular transduction mechanisms of adeno-associated viral vectors
Berry, G. E., & Asokan, A. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.08.001 · Cited by 100
Chowdhury, E. A., Meno‐Tetang, G. M. L., Chang, H. Y., Wu, S., Huang, H. W., Jamier, T., Chandran, J. S., & Shah, D. K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.017 · Cited by 82
Nieuwenhuis, B., Laperrousaz, E., Tribble, J. R., Verhaagen, J., Fawcett, J. W., Martin, K. R. G., Williams, P. A., & Osborne, A. (2023) · Gene Therapy · doi:10.1038/s41434-022-00380-z · Cited by 88
“Comparison of five promoters for transgene expression AAV2 cell entry is primarily achieved by binding heparin sulfate proteoglycans [77–81] and interacting with co-receptors on the cell surface such as the adeno-associated virus receptor [82, 83], the 37/67-kilodalton laminin receptor [84], αVβ5 integrin [85], hepato…”
BackgroundCell and gene therapy for kidney disease
Peek, J. L., & Wilson, M. H. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00702-3 · Cited by 90
Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS
Kanaan, N. M., Sellnow, R. C., Boye, S. L., Coberly, B., Bennett, A. D., Agbandje‐McKenna, M., Sortwell, C. E., Hauswirth, W. W., Boye, S. L., & Manfredsson, F. P. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.06.011 · Cited by 81
“For instance, the recently identified type I transmembrane protein KIAA0319L appears to be crucial for transduction for a number of AAV serotypes in a variety of cell types.(39) Nevertheless, further studies are needed to identify these non-HSPG-mediated pathways of AAV2 entry into neurons.”
BackgroundAlbright, B. H., Simon, K. E., Pillai, M., Devlin, G. W., & Asokan, A. (2019) · Journal of Virology · doi:10.1128/jvi.00332-19 · Cited by 72
Adeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 79
Li, S.-J., Vaughan, A., Sturgill, J. F., & Kepecs, Á. (2018) · Neuron · doi:10.1016/j.neuron.2018.05.028 · Cited by 78
Emerging approaches for restoration of hearing and vision
Kleinlogel, S., Vogl, C., Jeschke, M., Neef, J., & Moser, T. (2020) · Physiological Reviews · doi:10.1152/physrev.00035.2019 · Cited by 91
AAV-mediated gene therapy: Advancing cardiovascular disease treatment
Zhang, H., Qi, Z., Huang, B., Wang, Y., & Wang, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.952755 · Cited by 81
Niu, G.-J., Wang, S., Xu, J., Yang, M., Sun, J., He, Z.-H., Zhao, X., & Wang, J. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007558 · Cited by 67
Comparative Analysis of the Capsid Structures of AAVrh.10, AAVrh.39, and AAV8
Mietzsch, M., Barnes, C., Hull, J. A., Chipman, P. R., Xie, J., Bhattacharya, N., Sousa, D. R., McKENNA, R. V., Gao, G., & Agbandje‐McKenna, M. (2019) · Journal of Virology · doi:10.1128/jvi.01769-19 · Cited by 71
“It would be interesting to see whether the mutation of asparagine 472 in AAVRX1 (64) completely knocks out the capability to cross the BBB. Conclusions.”
BackgroundInfluentialAdeno-Associated Virus 2 at 2.8 ang
Lou, Z. Y., & Zhang, R. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6ih9/pdb · Cited by 66
Adeno-Associated Virus Genome Interactions Important for Vector Production and Transduction
Maurer, A. C., & Weitzman, M. D. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.069 · Cited by 76
Targeting muscle stem cell intrinsic defects to treat Duchenne muscular dystrophy
Dumont, N. A., & Rudnicki, M. A. (2016) · npj Regenerative Medicine · doi:10.1038/npjregenmed.2016.6 · Cited by 75
“Further studies are needed to improve AAV transduction efficiency into satellite cells and, in this regard, the recent identification of the AAV receptor is a step forward in the development of new tools to improve AAV efficacy.(33) Moreover, even with limited efficiency, it was showed that lentiviral-mediated gene de…”
MethodMaurer, A. C., Pacouret, S., Diaz, A. K. C., Blake, J., Andrés‐Mateos, E., & Vandenberghe, L. H. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.026 · Cited by 73
“, AAVR) to trigger its endocytosis (Pillay et al., 2016), endosomal escape (Girod et al.”
BackgroundBypassing pan-enterovirus host factor PLA2G16
Baggen, J., Liu, Y., Lyoo, H., van Vliet, A. L. W., Wahedi, M., de Bruin, J. W., Roberts, R. W., Overduin, P. P., Meijer, A., Rossmann, M. G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11256-z · Cited by 62
Mietzsch, M., Smith, J. K., Yu, J. C., Banala, V., Emmanuel, S. N., Jose, A., Chipman, P. R., Bhattacharya, N., McKENNA, R. V., & Agbandje‐McKenna, M. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.001 · Cited by 64
López-Gordo, E., Chamberlain, K., Riyad, J. M., Kohlbrenner, E., & Weber, T. (2024) · Viruses · doi:10.3390/v16030442 · Cited by 70
AAVR: A Multi-Serotype Receptor for AAV
Summerford, C., & Samulski, R. J. (2016) · Molecular Therapy · doi:10.1038/mt.2016.49 · Cited by 69
A comprehensive atlas of AAV tropism in the mouse
Walkey, C. J., Snow, K. J., Bulcha, J., Cox, A. R., Martinez, A. E., Ljungberg, M. C., Lanza, D. G., Giorgi, M. D., Chuecos, M. A., Alves‐Bezerra, M., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.041 · Cited by 68
AAV for Gene Therapy in Ocular Diseases: Progress and Prospects
He, X., Fu, Y., Ma, L., Yao, Y., Ge, S., Yang, Z. H., & Fan, X. (2023) · Research · doi:10.34133/research.0291 · Cited by 79
“AAVR, also known as KIAA0319L, is a newly identified multiserotype AAV receptor that is essential for AAV transduction and is found in a variety of organs, including the liver, lung, kidney, and retina [59,60].”
BackgroundExtensive Transduction and Enhanced Spread of a Modified AAV2 Capsid in the Non-human Primate CNS
Naidoo, J., Stanek, L. M., Ohno, K., Trewman, S., Samaranch, L., Hadaczek, P., O’Riordan, C. R., Sullivan, J., Sebastián, W. S., Bringas, J. R., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.008 · Cited by 63
The neuronal migration hypothesis of dyslexia: a critical evaluation 30 years on.
Guidi, L. G., Velayos‐Baeza, A., Martinez‐Garay, I., Monaco, A. P., Paracchini, S., Bishop, D. V. M., & Molnár, Z. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14149 · Cited by 59
“In addition, DCDC2 has been reported to be involved in synaptic transmission (Che, Girgenti, & LoTurco, 2014; Che, Truong, Fitch, & LoTurco, 2016), KIAA0319 in axon growth (Franquinho et al., 2017) and KIAA0319L as a cell surface adenovirus receptor (Pillay et al., 2016).”
BackgroundMoyer, T. C., Hoffman, B. A., Chen, W., Shah, I. S., Ren, X., Knox, T. M., Liu, J., Wang, W., Li, J., Khalid, H., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.046 · Cited by 68
“A plasmid encoding AAVR, a well-characterized AAV entry factor, 29 was used as a positive control.”
Diverse Viruses Require the Calcium Transporter SPCA1 for Maturation and Spread
Hoffmann, H.-H., Schneider, W. M., Blomen, V. A., Scull, M. A., Hovnanian, A., Brummelkamp, T. R., & Rice, C. M. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.09.002 · Cited by 62
“, Arenaviridae, Bunyaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, and Parvoviridae (Carette et al., 2009, 2011; Jae et al., 2013, 2014; Marceau et al., 2016; Pillay et al., 2016; Riblett et al., 2016; Savidis et al., 2016; Zhang et al., 2016).”
InfluentialHeparan sulfate is a clearance receptor for aberrant extracellular proteins
Itakura, E., Chiba, M., Murata, T., & Matsuura, A. (2020) · The Journal of Cell Biology · doi:10.1083/jcb.201911126 · Cited by 60
“…suggested that low density lipoprotein receptor-related protein 2 (LRP2) and Plexin A4 bind to Clusterin (Bell et al., 2007; Hammad et al., 1997; Kang et al., 2016; Zlokovic et al., 1996), the tissue distribution of LRP2 and Plaxin A4 is restricted (Lundgren et al., 1997; Pont´en et al., 2009).”
Itoga, C. A., Chen, Y., Fateri, C., Echeverry, P. A., Lai, J. M., Delgado, J., Badhon, S., Short, A. K., Baram, T. Z., & Xu, X. (2019) · The Journal of Comparative Neurology · doi:10.1002/cne.24676 · Cited by 64
“The method does introduce a degree of uncertainty: Whereas considerable efforts have been made to engineer AAV variants to allow improved viral tracing, several basic aspects of AAV cellular entry and tropism are still poorly understood (e.g., Pillay et al., 2016).”
MethodIlyinskii, P. O., Michaud, A. M., Roy, C. J., Rizzo, G. L., Elkins, S. L., Capela, T., Chowdhury, A. C., Leung, S. S., & Kishimoto, T. K. (2021) · Science Advances · doi:10.1126/sciadv.abd0321 · Cited by 56
Saurav, S., Tanwar, J., Ahuja, K., & Motiani, R. K. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101004 · Cited by 60
Michels, A., Frank, A. M., Günther, D. M., Mataei, M., Börner, K., Grimm, D., Hartmann, J., & Buchholz, C. J. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.014 · Cited by 61
“While future work needs to address the precise mechanism of cell entry of mCD8-AAV, previous work with a glutamate-receptor-targeted AAV, displaying DARPins on the N terminus of VP2, proved that entry of DARPin-targeted AAVs requires expression of the AAV receptor AAVR.(19,44) Irrespective of mechanism, the unpreceden…”
BackgroundHavlik, L. P., Simon, K. E., Smith, J. K., Klinc, K. A., Tse, L. V., Oh, D. K., Fanous, M. M., Meganck, R. M., Mietzsch, M., Kleinschmidt, J. A., et al. (2020) · Journal of Virology · doi:10.1128/jvi.00976-20 · Cited by 57
“In particular, cryo-EM studies have improved our understanding of the mechanisms by which glycans and AAVR are recognized by different AAV serotypes through divergent rules (10, 14–16).”
BackgroundInfluentialAdeno-Associated Virus Vector for Central Nervous System Gene Therapy
Zhu, D., Schieferecke, A. J., Lopez, P. A., & Schaffer, D. V. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.03.010 · Cited by 56
Pooled Screens Identify GPR108 and TM9SF2 as Host Cell Factors Critical for AAV Transduction
Meisen, W. H., Bahrami-Nejad, Z., Hardy, M., Zhao, H., Oliverio, O., Wang, S., Hale, C. M., Ollmann, M. M., & Collins, P. J. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.012 · Cited by 61
“…type and genomic perturbation strategy, we also took a different approach to identify genes involved in AAV2 transduction than that of Pillay et al. 1 In their study, they performed very stringent selection involving two rounds of sorting for transgene-negative (red fl uorescent protein [RFP] in…”
InfluentialPénzes, J. J., Chipman, P. R., Bhattacharya, N., Zeher, A., Huang, R. K., McKENNA, R. V., & Agbandje‐McKenna, M. (2021) · Journal of Virology · doi:10.1128/jvi.00843-21 · Cited by 57
“essential for AAV9 transduction in vivo in a knockout mouse model (56).”
BackgroundAdeno-Associated Virus (AAV) Gene Delivery: Dissecting Molecular Interactions upon Cell Entry
Large, E. E., Silveria, M., Zane, G. M., Weerakoon, O., & Chapman, M. S. (2021) · Viruses · doi:10.3390/v13071336 · Cited by 59
“For example, AAV2 was used to characterize the first AAV glycan attachment factors and deduce the first high-resolution AAV structure, and AAV2 served as the basis for the first genome-wide screen to identify protein entry receptors [22,24,36,37].”
BackgroundMethodInfluentialSelf-citationNanocarrier imaging at single-cell resolution across entire mouse bodies with deep learning
Luo, J., Molbay, M., Chen, Y., Horvath, I., Kadletz, K., Kick, B., Zhao, S., Al-Maskari, R., Singh, I., Ali, M., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-024-02528-1 · Cited by 53
“…of AAV2—the parent AAV subtype of Retro-AAV—including AAVR, membrane-associated heparan sulfate proteoglycan (HSPG), αVβ5 integrin and fibroblast growth factor receptor 1 (FGFR1) 74–78 , by pre-incubation of in vitro differentiated adipocytes with polyclonal antibodies (Supplementary Fig.”
In vivo site-specific engineering to reprogram T cells
Nyberg, W. A., Bernard, P.-L., Ngo, W., Wang, C. H., Ark, J., Rothrock, A., Borgo, G. M., Kimmerly, G. R., Jung, J. H., Allain, V., et al. (2026) · Nature · doi:10.1038/s41586-026-10235-x · Cited by 70
“As expected, KIAA0319L (also known as AAVR )—a well-established mediator of AAV entry and trafficking 38 —was depleted in both conditions.”
Humoral immune responses to AAV gene therapy in the ocular compartment
Whitehead, M., Osborne, A., Yu‐Wai‐Man, P., & Martin, K. (2021) · Biological Reviews · doi:10.1111/brv.12718 · Cited by 52
“First, the virus must bind to a cell and undergo endocytosis by utilising a number of primary receptors and co-receptors, many of which have not yet been identi fi ed (Pillay et al ., 2016).”
Metadata
- Authors
- Pillay, S., Meyer, N. L., Puschnik, A. S., Davulcu, O., Diep, J., Ishikawa, Y., Jae, L. T., Wosen, J. E., Nagamine, C. M., Chapman, M. S., & Carette, J. E.
- Affiliations
- Stanford Medicine (US)
- Oregon Health & Science University (US)
- The Netherlands Cancer Institute (NL)
- Corresponding author
- Chapman, M. S.
- Carette, J. E.
- ORCID
- Venue
- Nature
- Published
- 2016-01-27
- Volume
- 530
- Issue
- 7588
- Pages
- 108-112
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4962915
- OpenAlex
- W2266837556
- Cited by
- 532
- References
- 33
- Citations by year
- 2026: 58 · 2025: 51 · 2024: 63 · 2023: 60 · 2022: 36 · 2021: 47 · 2020: 57 · 2019: 50 · 2018: 43 · 2017: 37 · 2016: 28
- FWCI
- 43.04
- Type
- journal article
- Language
- en
- Update notices
- erratum (2016-09-28)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (5u19ai109662-05)
- National Institute of General Medical Sciences (R01GM066875)
- National Institute of Allergy and Infectious Diseases (DP2AI104557, U19-AI109662)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- adeno-associated virus, AAV receptor, AAV2, viral entry, host factors, endocytosis, AAV serotypes, gene therapy vectors, viral gene delivery
- MeSH terms
- Dependovirus, Animals, Antibodies, Cell Line, Endocytosis, Female, Humans, Male, Parvoviridae Infections, Receptors, Cell Surface, Receptors, Virus, Genetic Therapy, Gene Deletion, trans-Golgi Network, Mice, Virus Internalization, Viral Tropism, Host Specificity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.